GlassScriptPhysician profile
Kristeen Ogunsanwo
NPI 1992264048
$3,921.06
in general payments reported to CMS, 2019-2025
21 companies · $859 in 2025
The $859 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $685 · 2023: $730 · 2024: $1,647 · 2025: $859.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,236.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,236.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,141.70 | 2022-2025 | |
| Janssen Biotech, INC. | $479.63 | 2024-2025 | Tremfya, Stelara |
| Takeda Pharmaceuticals U.S.A., INC. | $423.73 | 2022-2025 | Entyvio, Gattex, Eohilia |
| E.R. Squibb & Sons, L.L.C. | $342.22 | 2022-2023 | Zeposia |
| Phathom Pharmaceuticals, INC. | $286.31 | 2024 | Voquezna |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $236.96 | 2022-2024 | Xifaxan |
| Conmed Corporation | $213.02 | 2022-2025 | Conmed Generators |
| Merck Sharp & Dohme LLC | $176.39 | 2023-2024 | Dificid |
| Gilead Sciences, INC. | $147.23 | 2022-2024 | Epclusa |
| Intercept Pharmaceuticals, INC. | $98.07 | 2022-2025 | Ocaliva |
| Celgene Corporation | $53.17 | 2023 | Zeposia |
| Smith+Nephew, INC. | $51.00 | 2025 | Renasys Touch, Pico 7 |
| Madrigal Pharmaceuticals | $49.72 | 2025 | Rezdiffra |
| Lemaitre Vascular, INC. | $43.69 | 2025 | Artegraft Vascular Graft |
| Regeneron Healthcare Solutions, INC. | $34.04 | 2024 | Dupixent |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avvisto Therapeutics, LLC | $33.55 | 2025 | Cycloset |
| Ardelyx, INC. | $28.88 | 2024 | Ibsrela |
| Genzyme Corporation | $27.81 | 2025 | |
| Tandem Diabetes Care, INC. | $21.33 | 2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Alcresta Therapeutics, INC. | $21.07 | 2023 | Relizorb |
| Boston Scientific Corporation | $11.54 | 2024 | Resolution 360 Ultra Clip |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kristeen Ogunsanwo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.